GOSS

AI Memo

Gossamer Bio

As of 2026-09-06/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Planned seralutinib NDA submission • 2026-09-30

Base target: $0 / p=50% prob

Biggest risk

The Q2 adjusted loss was worse than cited consensus, cash remains limited for a clinical-stage company, financing may dilute shareholders, and the NDA and approval path remain binary. Verified post-print analyst revisions and target changes are unavailable.

Invalidation

Break below $0 or thesis failure.

What would change my mind?

The September NDA plan, reacquired worldwide seralutinib rights and contingent financing could improve control, funding visibility and retained economics if regulatory execution progresses. [#PR-EARNINGS-2026-08-13]

Research note

Recommendation

—

Confidence

medium

As of

2026-09-06

Base target

p=50%

Bull target

p=20%

Bear target

p=30%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Financing and runway visibility
Conditional FDA review and approval path
The September NDA plan, reacquired worldwide seralutinib rights and contingent financing could improve control, funding visibility and retained economics if regulatory execution progresses.

BearKey bullets

Additional financing may be required and could materially dilute shareholders.
Clinical-stage biotech valuation is highly sensitive to binary trial and regulatory outcomes.
FDA concerns regarding statistical significance and treatment-effect magnitude could delay or impair review.

WatchKey bullets

Planned seralutinib NDA submission

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $0 (p=50%)

Target spread vs base: +150% / -67%

Scenario probabilities

Bull Target: $1 (p=20%)Base Target: $0 (p=50%)Bear Target: $0 (p=30%)

Commentary

News tone is moderately positive because of the September NDA plan, rights reacquisition and financing activity, but the Q2 adjusted loss miss and binary regulatory path temper conviction. Social sentiment, options skew, short interest, employee sentiment and verified analyst revisions are unavailable; missing data is not positive evidence.

As of 2026-09-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Financing and runway visibility
Conditional FDA review and approval path

Scenarios

Bull Target (Scenario probability)

$1 / p=20% prob

Base Target (Scenario probability)

$0 / p=50% prob

Bear Target (Scenario probability)

$0 / p=30% prob

Analysis 2026-09-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.35

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-30
Planned seralutinib NDA submission
Following FDA Pre-NDA Type B meeting minutes, Gossamer said it intends to submit an NDA for seralutinib in PAH in September 2026. Filing acceptance is not assured, and statistical significance and treatment-effect magnitude remain review issues. [#PR-EARNINGS-2026-08-13] [#SEC-8K-2026-07-27]
Prob 70.00% • Move 55.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

Financing and runway visibility
2026-08-24
Gossamer reported $57.0 million of cash, cash equivalents and marketable securities at June 30, 2026. The previously disclosed private-placement structure provides additional funding contingent on FDA acceptance and potential approval, but also introduces dilution and execution risk. [#SEC-8K-2026-08-21]
Prob 75% • Move 20% • Priced-in 70%

Long-term Catalysts

Months to a year

Conditional FDA review and approval path
2027-09-30
If the NDA is accepted, seralutinib could be eligible for an FDA approval decision in the third quarter of 2027. The outcome remains binary and depends on the FDA's review of the complete submission. [#PR-EARNINGS-2026-08-13]
Prob 35% • Move 150% • Priced-in 35%

Risks

Additional financing may be required and could materially dilute shareholders.
Clinical-stage biotech valuation is highly sensitive to binary trial and regulatory outcomes.
FDA concerns regarding statistical significance and treatment-effect magnitude could delay or impair review.
NDA filing acceptance and eventual approval are uncertain.
The company has limited cash relative to the duration and cost of a potential regulatory and commercial program.

Peers

Symbol	Summary
CSBR	Same-sector, similar-market-cap reference; direct clinical and indication comparability is not established.
CTOR	Same-sector, similar-market-cap reference; direct operating comparability is unconfirmed.
DWTX	Broad small-cap biotech reference with limited program comparability.
PLRX	Same-sector, similar-market-cap reference; direct program comparability is unconfirmed.
SPRO	Same-sector, similar-market-cap reference; useful mainly for broad event-driven biotech context.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-06

Loading AI feed…

Symbol

Summary

CSBR

Same-sector, similar-market-cap reference; direct clinical and indication comparability is not established.

CTOR

Same-sector, similar-market-cap reference; direct operating comparability is unconfirmed.

DWTX

Broad small-cap biotech reference with limited program comparability.

PLRX

Same-sector, similar-market-cap reference; direct program comparability is unconfirmed.

SPRO

Same-sector, similar-market-cap reference; useful mainly for broad event-driven biotech context.